Russia’s cancer vaccine shows effectiveness in preclinical trials
(MENAFN) Russia’s new cancer vaccine has demonstrated strong effectiveness in preclinical trials and is reportedly ready for deployment, according to the head of the Federal Medical-Biological Agency. The vaccine is awaiting final approval from the national Health Ministry.
The official highlighted that three years of preclinical testing confirmed both the safety and high efficacy of the vaccine, including repeated use. “The [trials] have proven the safety of the vaccine, including its repeated use, as well as its high efficiency, which was associated with a reduction in tumor size and a slowdown in tumor growth,” she said, noting that in some cancers, results reached 60-80%. “Studies have shown an increase in survival, which is also very important.”
Documents for clinical use were submitted to the Health Ministry at the end of summer, she added.
The vaccine, developed by the Gamaleya Research Institute of Epidemiology and Microbiology, is mRNA-based and uses artificial intelligence to train the patient’s immune system to target cancer cells. The institute’s head explained that the drug follows a unique regulatory pathway due to its innovative nature, stating, “This is a fundamentally different process from the registration of standard drugs.”
The Gamaleya Institute, which also created Russia’s Sputnik V Covid-19 vaccine, is currently working on an HIV vaccine using the same mRNA technology.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
